Enviro has now formally responded to Infiniteria’s request to terminate the ongoing corporate recons...
Redeye gives a preview ahead of Sdiptech's Q1 2026 report, due on April 28.
CDON delivered Q1 total GMV of SEK 394m , 7% better than our estimate of SEK 369m growing 16% y/y, d...
Redeye considers Binero’s Q1 trading update mixed, with positive signs from the underlying repositio...
* Sales SEK 226m (flat y-o-y, +2% vs. ABGSCe) * EBIT SEK 12m, 23% below ABGSCe on higher corporate c...
DT’s Q1 figures matched estimates as EBITA improved by EUR 1m y/y to EUR 2.
Physitrack’s Q1 2026 report landed close to our overall expectations, maintaining the stable and pro...
Vitrolife's Q1 report came in largely in line with consensus showing organic growth of 5% in local c...
Careium reported 6% y/y sales growth in Q1, leading to sales in line with SEBe.
Redeye provides its first take on Hansa Biopharma's Q1 report.
Bittium will publish its Q1'26 results on April 29.
Yesterday, NanoRepro announced an increase in its direct equity stake in DKW alongside its FY25p rev...
* Net sales SEK 584m, +1% vs ABGSCe, -2% vs Factset cons.
Fiskars Q1 adjusted EBIT of EUR 25.0m came 26% above Modular Finance consensus expectations with in...
Redeye updates on Evolution Q1-results which were close to our expectations.
Net sales and adjusted EBITA were around 5% below market consensus (LSEG) in Q1.
Sales grew by 7% vs. Cons was expecting 11% y/y after strong ending of the last year (Q3/25: 14.
Atria reported Q1 adjusted EBIT of EUR 13.9m, 6% above LSEG Data & Analytics consensus.
Redeye provides an update following Senzime’s Q1 2026 report.
* We expect 35% organic growth in Q1e * Q1 mix likely to be somewhat favourable * FVR of SEK 30-45 r...
